GSK PLC (LSE :GSK,NYSE :GSK) is showing a strong growth rate and increasing confidence in its HIV treatment, according to Jefferies analysts. However, they have cut their target share price due to long-term costs and risk concerns.
Jefferies maintained its rating of ‘hold’ and suggested that a 2022 price target at 1,575p be set. This is a drop of 4% from the original targets but still a higher price than its current price of 1,415p.
Jefferies stated that a lower target is due to higher costs starting at the end of 2022. He also mentioned that there were several factors Jefferies pointed out, such as the need to increase “commercial opportunity” through a series vaccine launches and an estimated charge between PS50mln and PS60mln for redeemed bonds of PS1.6bn in mid-November.
Analysts added that while GSK offers strong double-digit earnings growth through 2028, longer-term fundamental challenges “keeps us on the sidelines at an “Hold” rating.”
Jefferies stated that there are still setbacks in oncology, and the need for new licences, and bolt-on acquisitions, due to the expiration of its HIV patents.
Jefferies predicted GSK’s sales would rise 5% year-on-year, but pre-tax earnings should have increased by more than 10% when GSK reports its full-year results on February 1.
Jefferies stated Tuesday that after an event hosted by Emma Walmsley, chief executive, Jefferies believed: “GSK’s confidence in pipeline ultra-long-acting forms or self-administration has clearly grown that the potential to rapidly change the (existing treatment paradigm.
Walmsley spoke on Tuesday and stated that two-thirds the firm’s development portfolio is derived from HIV treatment. This was a suggestion that these markets are “attractive and growing,” with a total value of over PS100bn annually.
The CEO stated that these treatments also contributed 50% to GSK’s first nine months of 2022 sales.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.